We Think That There Are Some Issues For Shaanxi Panlong Pharmaceutical Group Limited By Share (SZSE:002864) Beyond Its Promising Earnings

The market for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd's (SZSE:002864) stock was strong after it released a healthy earnings report last week. Despite this, our analysis suggests that there are some factors weakening the foundations of those good profit numbers.

Check out our latest analysis for Shaanxi Panlong Pharmaceutical Group Limited By Share

To understand the value of a company's earnings growth, it is imperative to consider any dilution of shareholders' interests. As it happens, Shaanxi Panlong Pharmaceutical Group Limited By Share issued 9.8% more new shares over the last year. That means its earnings are split among a greater number of shares. To talk about net income, without noticing earnings per share, is to be distracted by the big numbers while ignoring the smaller numbers that talk to per share value. Check out Shaanxi Panlong Pharmaceutical Group Limited By Share's historical EPS growth by clicking on this link.

A Look At The Impact Of Shaanxi Panlong Pharmaceutical Group Limited By Share's Dilution On Its Earnings Per Share (EPS)

Shaanxi Panlong Pharmaceutical Group Limited By Share has improved its profit over the last three years, with an annualized gain of 38% in that time. In comparison, earnings per share only gained 19% over the same period. And over the last 12 months, the company grew its profit by 17%. On the other hand, earnings per share are pretty much flat, over the last twelve months. So you can see that the dilution has had a bit of an impact on shareholders.

In the long term, earnings per share growth should beget share price growth. So it will certainly be a positive for shareholders if Shaanxi Panlong Pharmaceutical Group Limited By Share can grow EPS persistently. But on the other hand, we'd be far less excited to learn profit (but not EPS) was improving. For the ordinary retail shareholder, EPS is a great measure to check your hypothetical "share" of the company's profit.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Shaanxi Panlong Pharmaceutical Group Limited By Share's Profit Performance

Shaanxi Panlong Pharmaceutical Group Limited By Share shareholders should keep in mind how many new shares it is issuing, because, dilution clearly has the power to severely impact shareholder returns. Because of this, we think that it may be that Shaanxi Panlong Pharmaceutical Group Limited By Share's statutory profits are better than its underlying earnings power. Nonetheless, it's still worth noting that its earnings per share have grown at 19% over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about Shaanxi Panlong Pharmaceutical Group Limited By Share as a business, it's important to be aware of any risks it's facing. Case in point: We've spotted 2 warning signs for Shaanxi Panlong Pharmaceutical Group Limited By Share you should be aware of.

This note has only looked at a single factor that sheds light on the nature of Shaanxi Panlong Pharmaceutical Group Limited By Share's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.